CN105147920A - Medicine used for treating tumors and preparation method thereof - Google Patents
Medicine used for treating tumors and preparation method thereof Download PDFInfo
- Publication number
- CN105147920A CN105147920A CN201510603191.5A CN201510603191A CN105147920A CN 105147920 A CN105147920 A CN 105147920A CN 201510603191 A CN201510603191 A CN 201510603191A CN 105147920 A CN105147920 A CN 105147920A
- Authority
- CN
- China
- Prior art keywords
- medicine
- tumor
- extractum
- manufacture method
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses medicine used for treating tumors and a preparation method thereof. The medicine is mainly prepared from, by weight, corium bufonis, cutch, dragon's blood, cynanchum paniculatum, musk and accessories. The medicine has the effects of clearing away heat and toxic materials, freeing orifices and activating blood and removing stasis and stopping pain, can effectively inhibit tumor cell proliferation and can be used for treating tumor patients. The medicine is good in treatment effect, high in specificity and small in tolerance and side effect.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of tumor and preparation method thereof, belong to field of pharmaceutical technology.
Technical background
Tumor (tumour) is one of maximum disease threatening human life's health, refer to that body is under the effect of the various tumorigenesis factor, the neoplasm (neogrowth) that local organization hyperplasia is formed, because this neoplasm is many in occupancy block-like protrusions, also claim vegetation (neoplasm).First the cause of cancer is equilibrium between yin and yang in human body, and histiocyte is under no carcinogenic factor long term, and cell mutation causes, it be mainly manifested in the abnormal and excessive hypertrophy of histiocyte.Cancerous tissue is also a part for human body in fact, and only at this imbalance between YIN and YANG of people, under generation-inhibition in five elements takes advantage of the prerequisite of insulting and changing, the immunosurveillance system of human body just can lose monitoring to it, develops as one pleases.In the course of time, cancerous cell is bred day by day, and tumor troop grows stronger day by day, and finally corrodes normal surrounding tissue, lot of energy and nutrition, affects the normal physiological metabolism of human body, causes body exhaustion gradually, finally causes death.
Along with scientific and technological progress, various tumor and chemotherapy regimen are constantly weeded out the old and bring forth the new, but therapeutic effect is still not fully up to expectations, and one of them important reason is exactly that tumor cell produces drug resistance to chemotherapeutics.Statistics shows, the tumor patient cause of the death is mostly relevant with drug resistance, and even some new drug just just finds drug resistance for clinical.Still there is the problems such as efficiency is low, poor selectivity, toxic and side effects are large in the treatment for malignant tumor.
Summary of the invention:
The object of the invention is to, a kind of medicine for the treatment of tumor and preparation method thereof is provided.Described medicine has heat-clearing and toxic substances removing, sensiblely invigorates blood circulation, effect of removing obstruction for relieving pain, can effective inhibition tumor cell propagation, can be used for treating tumor patient.Good effect, high specificity, drug resistance and side effect little.
For solving the problems of the technologies described above, the present invention realizes by the following technical solutions: a kind of medicine for the treatment of tumor, calculate by weight, be made primarily of dry maxima skin 1-20 part, catechu 10-50 part, Sanguis Draxonis 10-50 part, Radix Cynanchi Paniculati 20-80 part, Moschus 1-6 part and adjuvant.
In the medicine of aforesaid treatment tumor, calculate by weight, be made primarily of dry maxima skin 5-15 part, catechu 25-35 part, Sanguis Draxonis 25-35 part, Radix Cynanchi Paniculati 45-55 part, Moschus 2-4 part and adjuvant.
In the medicine of aforesaid treatment tumor, calculate by weight, be made primarily of dry maxima skin 10 parts, 30 parts, catechu, Sanguis Draxonis 30 parts, Radix Cynanchi Paniculati 50 parts, 3 parts, Moschus and adjuvant.
A manufacture method for the medicine of aforesaid treatment tumor, gets above-mentioned raw materials, adds customary adjuvant, and also can not add adjuvant, conveniently technique is processed, and makes pharmaceutical preparation.
In the manufacture method of the medicine of aforesaid treatment tumor, described pharmaceutical preparation is oral formulations.
In the manufacture method of the medicine of aforesaid treatment tumor, described oral formulations is capsule, granule, tablet, pill, powder or cream.
In the manufacture method of the medicine of aforesaid treatment tumor, the manufacture method of described capsule is: get above-mentioned medical material, with the alcohol reflux 2 times of 6 times amount 70%, and each 1 hour, extracting liquid filtering merging filtrate, filtrate recycling ethanol and when being condensed into 50-60 DEG C relative density be the extractum of 1.20-1.25, separately get the starch of extractum amount 30% and the magnesium stearate of 0.7% and extractum and mix, with the alcohol granulation of 60%, dry, pulverize, filled capsules, to obtain final product.
In the manufacture method of the medicine of aforesaid treatment tumor, the manufacture method of described granule is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filters, and merges decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, the starch of extractum and extractum amount 20% and the dextrine powder mixing granulation of 20%, dry, to obtain final product.
In the manufacture method of the medicine of aforesaid treatment tumor, the manufacture method of described tablet is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filter, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, and the starch of extractum and above-mentioned mixed powder and extractum amount 20% mixes, tabletting, film coating, to obtain final product.
In the manufacture method of the medicine of aforesaid treatment tumor, the manufacture method of described pill is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filter, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, and extractum mixes general ball with the starch of extractum amount 15%, dry, coating, to obtain final product.
Medicine of the present invention is made primarily of dry maxima skin, catechu, Sanguis Draxonis, Radix Cynanchi Paniculati and Moschus.Wherein, Cutis Bufonis " herbal classic is met former ") be the skin of Bufonidae animal Bufo siccus or Bufo melanostictus etc.There is heat-clearing and toxic substances removing, effect of diuretic relieving distension.Can be used for treating carbuncle, toxic swelling, scrofula, tumor, infantile malnutrition abdominal distention, the diseases such as chronic tracheitis.1. " detailed outline is picked up any lost article from the road ": paste large poison, can draw out pus by applying a plaster to the affected part.2. " book on Chinese herbal medicine asks former ": paste skin ulcer scrofula, moxa-moxibustion.3. " Zhejiang Chinese medicine handbook ": be children's's five kinds of child malnutrition infantile convulsion medicine, again can and urine, disappear abdominal distention.(" travelling box inspection secret ") 2. controls carbuncle skin ulcer: large Rana limnocharis one, stripping whole body leprosy skin, and lid pastes the open sore part, on toad skin with pin by prickle number hole, to go out poison, conscious peace and quiet, and can climb the open sore part, do not make and growing up.(" the secret red medicine Letterhead of spirit ") 3. detumescence moves back poison: dry maxima skin is regardless of how many, and grind as end, the Liquor Flos Lonicerae Distillata dresses.(《 Yao Lian opens secret " golden toad falls apart) 4. control intestinal head and endure out: Cutis Bufonis a slice, burn smoked very place in bottle.Acrid in the mouth, warm in nature.Adapt to hepatitis, hepatocarcinoma, hepatic ascites, skin carcinoma, gastric cancer, pulmonary carcinoma, the esophageal carcinoma, intestinal cancer etc., also have significant curative effect to stupid evil diseases such as nephropathy cyclomastopathy, edema, edema, hysteromyoma.Catechu is peeling branch, the dry dry soft extracts of leguminous plant catechu Acaciacatechu (L.f.) Willci..Gather winter branch, dry, removing crust, is chopped to bulk, decocts with water, concentrated, dry.Be distributed in south of Yunnan area, there is cultivation in Hainan.There is promoting blood circulation and stopping pain, hemostasia and promoting granulation, removing dampness sore, effect of removing heat from the lung and dissipating phlegm.Flutter the pain of injury for falling, traumatic hemorrhage, hematemesis and epistaxis, skin infection is not held back, eczema, eczema, cough due to lung-heat.Nature and flavor: bitter, puckery, are slightly cold.Gui Jing: return lung, heart channel.Sanguis Draxonis, Chinese medicine name, latin name: DaemonoropsdracoBl, the resin oozed out for babassu Sanguis Draxonis fruit is through being processed into.Be distributed in the places such as Indonesia Java, Sumatera, Borneo.There is analgesic therapy of invigorating blood circulation, removing stasis to stop bleeding, effect of promoting tissue regeneration and ulcer healing.For traumatic injury, trusted subordinate's stasis of blood pain, traumatic hemorrhage, skin infection is not held back.Nature and flavor: sweet, salty are flat.Gui Jing: GUIXIN, Liver Channel.This product is circle square or square brick shape in class slightly, and surface is dark red, glossy, with the Hydrargyri Oxydum Rubrum because of friction.Matter is hard and crisp, and the plane of disruption is red, and levigation is brick-red.Feeble QI, lightly seasoned.Insoluble in water, soften in the hot water.Compendium of Material Medica: the fat liquid of wood, as the human fat and blood of people, its sweet-salty and walk blood, lid hands, foot faint cloudy medicine also.The all main blood Gu Er of liver and pericardium." herbal classic is met former ": the folding that cures the wound is beaten and damaged all pain, and vim and vigour stir thorn, and interior blood trouble is gathered, and should wine clothes.Though the main disorders of blood of Olibanum, Myrrha and double enter edema caused by disorder of QI, this then special in Liver Channel blood system also.But property is the most anxious can draw pus, should not take more.The person of same Olibanum, Myrrha use in its Yang-strengthening drug, gets to be in harmonious proportion vim and vigour and without the trouble of stopping up poison of being detained.Radix Cynanchi Paniculati, formal name used at school Cynanchumpaniculatum (Bunge) Kitagawa.Another name: few Diao Zhu, Folium Bambusae Herba Asari.Perennial vertical herbage.Be grown in endroit and thick grass.Adaptability is comparatively strong, likes warm, moistening environment, but avoids hydrops, and heat-resisting tolerance to cold is strong, all can plant in various places, north and south.But with humus soil or fertile deep, well-drained sandy loam growth better.Surface yellowish white is to light brown yellow, or brown; The vertical wrinkle that tool is fine, and have very thin fibrous root.Matter is crisp, frangibility, section mealiness, skin zone's off-white color or yellow-white, and cambium ring light brown, woody part is tiny.Gas is fragrant, and taste is micro-pungent cool.Meridian distribution of property and flavor: pungent, temperature.Return liver, stomach warp.For various pain diseases such as rheumatic arthralgia, lumbago, traumatic injury pain, abdominal pain, toothache.Radix Cynanchi Paniculati has good wind-expelling pain-stopping effect, is widely used for the various pain diseases caused by rheumatism, cold coagulation, the stagnation of QI, blood stasis.Also for postoperative pain and cancerous protuberance pain, certain analgesic effect is had.Can apply by single, or with demonstrate,proving the relevant medicine of compatibility.By dermatosiss such as eczema, rubella wheal, stubborn dermatitis.Radix Cynanchi Paniculati has dispelling wind for relieving itching effect.Can be alone for oral administration or decoct soup washout, also can the medicine of the eliminating damp-heat such as compatibility Radix Sophorae Flavescentis, the Fructus Kochiae, Cortex Dictamni.In addition, Radix Cynanchi Paniculati can also antidote against snake bite, and controls venom.Can with Herba Lobeliae Chinensis with using for oral administration or external." herbal classic ": main diseases due to noxious agents produced by various parasites, epidemic, evil gas, pyrexial malaria, main note easily dies, and crys, sad, dimly." Guizhou side's medicine among the people collection ": restore menstrual flow and invigorate blood circulation.Control red collapsing, leucorrhea.Guangzhou army " conventional Chinese herbal medicine handbook ": wind-expelling pain-stopping, removing toxic substances and promoting subsidence of swelling, promoting the flow of QI in the collateral by warming the meridian.Control venom, rheumatic ostalgia, heart peratodynia, treating swelling and pain by traumatic injury, herpes zoster, cirrhotic ascites, menoxenia, dysmenorrhea." Jilin Chinese herbal medicine ": diuresis, strong, sedation-analgesia, dissipating blood stasis of dispeling cold, antidotes against snake bite, dredging collateral and blood.Control beriberi, edema, ascites, distension, abdominal pain due to cold.Moschus, outer literary fame musk is the one of Chinese crude drug, and its medicinal source is Moschus moschiferous section animal, as the dry secretions in the male body glandular sac that woods Moschus moschiferous, horse Moschus moschiferous or former Moschus moschiferous etc. are ripe.Moschus is warm in nature, nontoxic, bitter in the mouth.Enter the heart, spleen, Liver Channel, have and have one's ideas straightened out, ward off dirty, dredging collateral, scattered silt function.Cure mainly apoplexy, syncope due to accumulation of phlegm, infantile convulsion, attacked by pestiferous factors unhappiness, trusted subordinate's sudden pain, traumatic injury, swollen ulcer drug.Many clinical materials show, during patients with coronary heart disease angina pectoris attacks, or be in faint shock time, take with Moschus be main component Soviet Union close ball, the state of an illness can be eased; Talk in ancient book " Elementary Medicine " ' Moschus, the saturating key of clearance, above reaches muscle.Inside enter bone marrow ... '.Compendium of Material Medica cloud: ' ... lid Moschus is walked to alter, and can lead to the unfavorable of all keys, the heap soil or fertilizer over and around the roots of opening meridians is held back '.Its meaning says that Moschus can enter muscle and bone marrow very soon, can give full play to the property of medicine.During treatment sore, Moschus of adding some points in right amount in medicine, drug effect is obvious especially.The first aid medicines such as cardiac tonic analeptic made by Western medicine Moschus.
The present invention adopts above-mentioned raw materials to make medicine, and each component has good synergism, is monarch with Cutis Bufonis, heat-clearing and toxic substances removing, inducing diuresis to remove edema; Moschus is minister, helps Cutis Bufonis, inducing resuscitation, promoting blood circulation to restore menstrual flow, reducing swelling and alleviating pain, keep away dislike virus killing, walk to alter up and down, interior deep key internal organs, outer thorough skin and flesh grain; Assistant is with catechu, Sanguis Draxonis, and special promoting the circulation of blood divides, vanishing sputum and dispelling knot, hemostasis analgesic therapy, promoting blood circulation to remove obstruction in the collateral; Make with Radix Cynanchi Paniculati, eliminating dampness and promoting diuresis, removing toxic substances and promoting subsidence of swelling, promoting the circulation of QI to relieve pain, prescription is investigated, and plays heat-clearing and toxic substances removing altogether, sensiblely to invigorate blood circulation, the merit of removing obstruction for relieving pain.Such as the lump caused because of " expectorant, the stasis of blood, poison, heat, water ", edema, blood disorder, pain and meet above-mentioned pathogenesis person, all can use we.The various cancerous protuberances of Western medicine diagnose meet above-mentioned proposita, all can use.
Compared with prior art, the present invention adopts above raw material to make medicine, and each component has good synergism, and all medicines share, and play heat-clearing and toxic substances removing altogether, sensiblely invigorates blood circulation, effect of removing obstruction for relieving pain, can effective inhibition tumor cell propagation, can be used for treating tumor patient.Good effect, high specificity, drug resistance and side effect little, reach goal of the invention.
Applicant carried out following experiments, provable the present invention has effective effect;
Experimental example effect experiment
1 experiment material and instrument
1.1 Experimental agents and reagent medicine of the present invention, make by embodiment 1; Cyclophosphamide for injection (CTX), Hengrui Medicine Co., Ltd., Jiangsu Prov. produces, lot number 05022421; Batilol tablet, Jiangsu Pengyao Pharmaceutical Co., Ltd. produces, lot number 0704041; Giemsa (Giemsa), Chemical Reagent Co., Ltd., Sinopharm Group produces, lot number F20070402; RPMI-1640, Gibco company produces; Concanavalin A (conA), Sigma company produces; Mice IL-2 and TNF-aELISA test kit, R & D company produces.
1.2 laboratory animals. male mice in kunming, SPF level, body weight 18 ~ 22g; Adult Hen and Cavia porcellus, provided by Institute of Experimental Animals, Chinese Academy of Medical Sciences, and independent isolating raises (raising of cage tool), ambient temperature is 20 ~ 25 DEG C, humidity >50%, natural lighting (12h every day), ad lib is drunk water.
1.3 tumor cell lines. murine sarcoma S-180 cell strain, is provided by institute of Materia Medica,Chinese Academy of Medical Sciences.
1.4 experimental apparatus .ELX800UV type microplate reader, PCE 1 automatic blood cell counter, wJ mono-301TC0.Incubator, AR2140 electronic balance, the miniature vortex mixed instrument of WH 1, super-clean bench, centrifuge etc.
2 experimental techniques and interpretation of result
2.1HT is on the impact of mice with tumor Peritoneal Macrophage Phagocytosis
2.1.1 the foundation of murine sarcoma S-180 Replanting model mice
The S-180 sarcoma mice dislocation of inoculation 7d put to death, fixing, sterilization, aseptic aspiration ascites, becomes 5 × 106/L tumor cell suspension with normal saline dilution, and it is subcutaneous to be only inoculated in healthy kunming mice right fore axillary fossa with 0.2mE/.
2.1.2 animal grouping and administration
50 male mice in kunming, 5 groups are divided at random by body weight, often organize 10, be respectively model group, positive drug cyclophosphamide group (0.05g/kg), the high, medium and low dosage group (2.00 of the present invention, 1.00,0.50g/kg), except positive control drug group is lumbar injection, all the other respectively organize and press the corresponding each medicine of 1mL/100g gavage, model control group gavage isometric solvent control every day.1 time/d, successive administration 10d.
1h after last administration, the chicken red blood cell 0.2mL of each group of lumbar injection 5%, gently rub abdominal part both sides, after 8h, animal dislocation is put to death, sterilization abdominal part, cuts off skin, through intraperitoneal injection of saline 2mL, extract abdominal cavity washing liquid, getting 0.2mL drips on microscope slide, 2/only. be placed in 5%CO2 incubator 37 DEG C of incubation 30min, take out, drop into rinsing in normal saline, remove the cell of non-paster, dry, with the fixing 5min of acetone one methanol solution (1:1), again with Ji nurse Sa dye liquor dyeing 5min, distilled water rinsing, to dry.Often open slice, thin piece and examine under a microscope 100 macrophage numbers, calculate phagocytic rate and phagocytic index.Experimental data adopts SPSS13.0 statistics software processes, and adopt one factor analysis of variance between group, numerical value represents with (mean ± standard deviation), lower same.
Phagocytic rate=(engulfing the macrophage number of the macrophage number/counting of chicken red blood cell) * 100%,
Phagocytic index=(macrophage number engulfs the macrophage number of the sum/counting of chicken red blood cell) * 100%.
Experimental result shows: phagocytic percentage and the phagocytic index of each dosage group of medicine of the present invention are all significantly higher than model group (P<0.05), and middle dosage group is particularly remarkable. the visible each dosage group of medicine of the present invention can strengthen the phagocytic function of mice with tumor peritoneal macrophage. and in table 1.
Table 1 is on the impact of mice with tumor phagocytic rate and phagocytic index
Note: compare with model group, * p<0.05; Blank shows not no this item.
2.2 impacts on mice with tumor Function of lymphocyte transform and inflammatory cytokine
2.2.1 animal model
Grouping and administration the same, successive administration 10d. is 1h after last administration, puts to death mice, take tumor and weigh, calculate tumour inhibiting rate after each group eye socket gets blood.
Tumour inhibiting rate=(model group tumor weight-test group tumor weight)/model group tumor heavy * 100%.
2.2.2 Function of lymphocyte transform measures
2.2.2.1 prepare, splenocyte suspension is aseptic gets spleen, with shredding after PBS cleaning, grinding, filter, the centrifugal 5min of 1000r/min, abandon supernatant, with the cell oscillation 30s hypotonic dissolution of 0.4mL distilled water by precipitation, then add 0.4mL1.7% hypertonic saline, make solution recover isotonic, the centrifugal 5min of 1000r/min again, cleans with RPMI-1640 culture fluid and adjusts cell concentration to be 5 × 10
6/ L, is placed in 5%CO2 incubator and cultivates, stand-by.
2.2.2.2 Function of lymphocyte transform measures and adjusts cellular elements concentration to be 5 × 10 RPMI mono-RPMI-1640 of the mouse boosting cell suspension of preparation containing 10% calf serum
6/ L, add in 96 well culture plates, every hole adds the ConA that 100 microlitre mass concentrations are 2.5 micrograms per millilitre, in 5%C02 incubator after 37 DEG C of cultivation 48h, supernatant is abandoned after imposite is centrifugal, it is the MTT of 5mg/mL that every hole adds 10 anus L mass concentrations, continues to cultivate 4h, abandons supernatant after imposite is centrifugal, add 100 microlitre DMSO, vibrate 10min on micro oscillator, in wavelength 570am place densitometric value (OD) in microplate reader, repeats experiment 3 times.
2.2.3IL-2 with the mensuration of TNF-α
By blood in the centrifugal 15min of 3500r/min, separation of serum, requires to measure IL-2 and TNF-α according to ELISA kit.
Experimental result shows: medicine of the present invention can significantly improve the Function of lymphocyte transform of mice with tumor, wherein high and low dose group compares with model group and has significant difference (P<0.05), and positive control drug group Function of lymphocyte transform comparatively model group reduce further; In medicine of the present invention, low dose group significantly can promote the generation of mice with tumor IL-2 and TNF-α, compares have significant difference (P<0.05) with model group; Medicine of the present invention has obvious tumor-inhibiting action, and visible medicine of the present invention can improve the cellular immune function of mice with tumor, and tumor-inhibiting action is remarkable. in table 2.
Table 2 is on the impact of mice with tumor Function of lymphocyte transform and inflammatory cytokine
Note: compare with model group, * is P<0.05, * * P<0.01, * * * P<0.001.
3 results
Result shows, the growth of medicine of the present invention each dosage group to little s-180 sarcoma has obvious inhibitory action, high dose group inhibitory rate 54.6%.Effectively can breed by inhibition tumor cell, can be used for treating tumor patient.The each dosage group of medicine of the present invention all can improve phagocytic function and the T lymphopoiesis ability of mice with tumor macrophage, the content (P<0.05-0.001) of IL-2 and TNF-α in increasing serum, and promote the secretion of IL-2 and TNF-α further, then by the biological efficiency of the two, the regulation and control of organism immune response are participated in.
Below in conjunction with embodiment, invention is further described, but not as the foundation limited the present invention.
Detailed description of the invention:
Embodiment 1.
Formula: dry maxima skin 100g, catechu 300g, Sanguis Draxonis 300g, Radix Cynanchi Paniculati 500g and Moschus 30g.
Technique: get said medicine, with the alcohol reflux 2 times of 6 times amount 70%, each 1 hour, extracting liquid filtering, filtrate recycling ethanol and when being condensed into 50-60 DEG C relative density be the extractum of 1.20-1.25, separately get the starch of extractum amount 30% and the magnesium stearate of 0.7% and extractum to mix, with the alcohol granulation of 60%, dry, pulverize, filled capsules, obtains capsule.
Specification: 0.3g/ grain.
Usage and dosage: oral, 2 ~ 3 times on the one, each 3.
Embodiment 2.
Formula: dry maxima skin 150g, catechu 350g, Sanguis Draxonis 350g, Radix Cynanchi Paniculati 550g and Moschus 40g.
Technique: get said medicine, adds 10 times amount soak by water 3 times, each 1.5h, filter, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, the starch of extractum and extractum amount 20% and the dextrine powder mixing granulation of 20%, dry, obtain granule.
Specification: 10g/ bag.
Usage and dosage: every day 2 times, each 10-20g, oral.
Embodiment 3.
Formula: dry maxima skin 50g, catechu 250g, Sanguis Draxonis 250g, Radix Cynanchi Paniculati 450g and Moschus 20g.
Technique: get said medicine, adds 10 times amount soak by water 3 times, each 1.5h, filters, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, and the starch of extractum and above-mentioned mixed powder and extractum amount 20% mixes, tabletting, film coating, obtains tablet.
Specification: 0.3g/ sheet.
Usage and dosage: oral, 2 ~ 3 times on the one, each 3.
Claims (10)
1. treat a medicine for tumor, it is characterized in that: calculate by weight, be made primarily of dry maxima skin 1-20 part, catechu 10-50 part, Sanguis Draxonis 10-50 part, Radix Cynanchi Paniculati 20-80 part, Moschus 1-6 part and adjuvant.
2. the medicine for the treatment of tumor as claimed in claim 1, is characterized in that: calculate by weight, is made primarily of dry maxima skin 5-15 part, catechu 25-35 part, Sanguis Draxonis 25-35 part, Radix Cynanchi Paniculati 45-55 part, Moschus 2-4 part and adjuvant.
3. the medicine for the treatment of tumor as claimed in claim 2, is characterized in that: calculate by weight, is made primarily of dry maxima skin 10 parts, 30 parts, catechu, Sanguis Draxonis 30 parts, Radix Cynanchi Paniculati 50 parts, 3 parts, Moschus and adjuvant.
4. a manufacture method for the medicine of the treatment tumor according to any one of claim 1-3, is characterized in that: get above-mentioned raw materials, adds customary adjuvant, also can not add adjuvant, conveniently technique is processed, and makes pharmaceutical preparation.
5. the manufacture method of the medicine for the treatment of tumor as claimed in claim 4, is characterized in that: described pharmaceutical preparation is oral formulations.
6. the manufacture method of the medicine for the treatment of tumor as claimed in claim 5, is characterized in that: described oral formulations is capsule, granule, tablet, pill, powder or cream.
7. the manufacture method of the medicine for the treatment of tumor as claimed in claim 6, it is characterized in that: the manufacture method of described capsule is: get above-mentioned medical material, with the alcohol reflux 2 times of 6 times amount 70%, each 1 hour, extracting liquid filtering merging filtrate, filtrate recycling ethanol and when being condensed into 50-60 DEG C relative density be the extractum of 1.20-1.25, separately get the starch of extractum amount 30% and the magnesium stearate of 0.7% and extractum and mix, with the alcohol granulation of 60%, dry, pulverize, filled capsules, to obtain final product.
8. the manufacture method of the medicine for the treatment of tumor as claimed in claim 6, it is characterized in that: the manufacture method of described granule is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filters, and merges decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, the starch of extractum and extractum amount 20% and the dextrine powder mixing granulation of 20%, dry, to obtain final product.
9. the manufacture method of the medicine for the treatment of tumor as claimed in claim 6, it is characterized in that: the manufacture method of described tablet is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filter, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, and the starch of extractum and above-mentioned mixed powder and extractum amount 20% mixes, tabletting, film coating, to obtain final product.
10. the manufacture method of the medicine for the treatment of tumor as claimed in claim 6, it is characterized in that: the manufacture method of described pill is: get said medicine, add 10 times amount soak by water 3 times, each 1.5h, filter, merge decoction liquor, when being condensed into 50-60 DEG C, relative density is the extractum of 1.15-1.20, and extractum mixes general ball with the starch of extractum amount 15%, dry, coating, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510603191.5A CN105147920B (en) | 2015-09-21 | 2015-09-21 | Medicine for treating tumor and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510603191.5A CN105147920B (en) | 2015-09-21 | 2015-09-21 | Medicine for treating tumor and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105147920A true CN105147920A (en) | 2015-12-16 |
| CN105147920B CN105147920B (en) | 2020-02-14 |
Family
ID=54789192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510603191.5A Active CN105147920B (en) | 2015-09-21 | 2015-09-21 | Medicine for treating tumor and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105147920B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106474362A (en) * | 2016-01-12 | 2017-03-08 | 宋林萍 | A kind of Chinese medicine composition treating tumor and its preparation and preparation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101293060A (en) * | 2008-06-11 | 2008-10-29 | 许宗宽 | Traditional Chinese medicine for treating cytology specification adenocarcinoma |
| CN101342194A (en) * | 2008-08-29 | 2009-01-14 | 陕西东泰制药有限公司 | Traditional Chinese medicine preparation for treating median or late-stage malignant tumors, chronic hepatitis B, and preparation method thereof |
| CN103977351A (en) * | 2014-05-23 | 2014-08-13 | 李绍礼 | Medicine composition for treating liver cancer |
| CN104436018A (en) * | 2014-11-10 | 2015-03-25 | 贵阳中医学院 | Medicine for treating tumors and preparation method thereof |
| CN104623432A (en) * | 2015-01-01 | 2015-05-20 | 县三信 | Traditional Chinese medicine composition for performing elimination treatment on tumor |
-
2015
- 2015-09-21 CN CN201510603191.5A patent/CN105147920B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101293060A (en) * | 2008-06-11 | 2008-10-29 | 许宗宽 | Traditional Chinese medicine for treating cytology specification adenocarcinoma |
| CN101342194A (en) * | 2008-08-29 | 2009-01-14 | 陕西东泰制药有限公司 | Traditional Chinese medicine preparation for treating median or late-stage malignant tumors, chronic hepatitis B, and preparation method thereof |
| CN103977351A (en) * | 2014-05-23 | 2014-08-13 | 李绍礼 | Medicine composition for treating liver cancer |
| CN104436018A (en) * | 2014-11-10 | 2015-03-25 | 贵阳中医学院 | Medicine for treating tumors and preparation method thereof |
| CN104623432A (en) * | 2015-01-01 | 2015-05-20 | 县三信 | Traditional Chinese medicine composition for performing elimination treatment on tumor |
Non-Patent Citations (1)
| Title |
|---|
| 雷永仲 等，: "中医药治疗恶性肿瘤存活五年以上42例临床分析", 《辽宁中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106474362A (en) * | 2016-01-12 | 2017-03-08 | 宋林萍 | A kind of Chinese medicine composition treating tumor and its preparation and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105147920B (en) | 2020-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101804166B (en) | Traditional Chinese medicine composition for treating dermatitis and eczema of infants | |
| CN102078473B (en) | Traditional Chinese medicine preparation for treating chronic hepatitis b and preparation method thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN102178781A (en) | Chinese medicine composition for treating scrotum eczema and preparation method thereof | |
| CN104888157A (en) | Traditional Chinese medicine preparation for treating hysteromyoma and preparation method thereof | |
| CN105147920A (en) | Medicine used for treating tumors and preparation method thereof | |
| CN104274592A (en) | Medicine for treating tinea versicolor | |
| CN103520697A (en) | Traditional Chinese medicine for treating qi-yin deficiency syndrome type chest stuffiness and pains | |
| CN102805825B (en) | Drug for curing cutaneous pruritus and preparation method thereof | |
| CN102579818A (en) | Traditional Tibetan medicine composition, preparation method thereof and application | |
| CN101028445B (en) | Chinese medicine for treating ichthyosis | |
| CN103520352A (en) | Traditional Chinese medicine for treating venation stasis and obstruction symptom type chest stuffiness and pains | |
| CN103520644B (en) | Traditional Chinese medicine composition used for treating phlegm stagnation type hyperlipidaemia and preparation method of composition | |
| CN102727805A (en) | Cancer treating medicine | |
| CN100496522C (en) | Medicinal composition containing propolis, preparation method and use thereof | |
| CN100459993C (en) | Compound Chinese medicine for treating bone stitch and its preparation | |
| CN106334140A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN105343582A (en) | Medicine for treating tetanus and preparation method thereof | |
| CN105412825A (en) | Drug for treating hyperlipidaemia and preparation method thereof | |
| CN104666582B (en) | A kind of health products preparation method and corresponding health products for strengthen immunity | |
| CN105582379A (en) | Traditional Chinese medicine composition for treating liver-stomach disharmony and preparation method of traditional Chinese medicine composition | |
| CN104906467A (en) | Traditional Chinese medicine composition for treating gout and preparation method | |
| CN105311466A (en) | Preparation for resolving hard lumps of patients with lymph cancer and preparing method of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 550002 No. 50 East City Road, Guizhou, Guiyang Patentee after: Guizhou University of Traditional Chinese Medicine Address before: 550002 No. 50 East City Road, Guizhou, Guiyang Patentee before: GUIYANG COLLEGE OF TRADITIONAL CHINESE MEDICINE |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 550025 No.4, Dongqing Road, Huaxi University Town, Huaxi District, Guiyang City, Guizhou Province Patentee after: Guizhou University of Traditional Chinese Medicine Address before: 550002 No. 50 East City Road, Guizhou, Guiyang Patentee before: Guizhou University of Traditional Chinese Medicine |
|
| CP02 | Change in the address of a patent holder | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151216 Assignee: First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine Assignor: Guizhou University of Traditional Chinese Medicine Contract record no.: X2021520000001 Denomination of invention: The invention relates to a medicine for treating tumor and a preparation method thereof Granted publication date: 20200214 License type: Common License Record date: 20210305 |
|
| EE01 | Entry into force of recordation of patent licensing contract |